12th Alzheimer's and Parkinson's Drug Development Summit
Evvnt Promotion / evvnt
Archivio
23.04.2024 - 25.04.2024 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
Temi della conferenza
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/2146026-3?pid=4832
Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more
Brochure: https://go.evvnt.com/2146026-3?pid=4832
Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/2146026-2?pid=4832
Ms. Erin Thomas
Medicina General
Lingua
Inglese
Inglese
Quote del Congresso
USD 2999.00 - USD 5197.00
USD 2999.00 - USD 5197.00
I partecipanti attesi
1000 - 1000
1000 - 1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
